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Abstract
DING proteins constitute an interesting family, owing to their intriguing and important activities. However, after a decade of
research, little is known about these proteins. In humans, at least five different DING proteins have been identified, which
were implicated in important biological processes and diseases, including HIV. Indeed, recent data from different research
groups have highlighted the anti-HIV activity of some DING representatives. These proteins share the ability to inhibit the
transcriptional step of HIV-1, a key step of the viral cycle that is not yet targeted by the current therapies. Since such
proteins have been isolated from humans, we undertook a comprehensive study that focuses on the relationship between
these proteins and HIV-infection in an infectious context. Hence, we developed a home-made ELISA for the quantification of
the concentration of DING proteins in human serum. Using this method, we were able to determine the concentration of
DING proteins in healthy and HIV-infected patients. Interestingly, we observed a significant increase of the concentration of
DING proteins in non treated and treated HIV-infected patients compared to controls. In addition, cell cultures infected with
HIV also show an increased expression of DING proteins, ruling out the possible role of antiretroviral treatment in the
increase of the expression of DING proteins. In conclusion, results from this study show that the organism reacts to HIV-
infection by an overexpression of DING proteins.
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Introduction
DING proteins constitute an intriguing family of proteins that
were named for their highly conserved N-terminal sequence
DINGGG- [1,2]. The first DING protein was discovered in
humans [3], and other members have been further identified in the
three kingdoms of life [4]. To date, about 40 different DING
proteins have been reported, mainly in eukaryotes [5]. Despite the
wide presence of these proteins, DING genes have never been
identified in eukaryotes, even in the human genome [5]. Attempts to
sequence eukaryotic DING genes have encountered many
difficulties since no ORF or locus coding these proteins has been
identified. Nevertheless, some partial nucleic sequences have been
amplified from humans and plants [4] [Genbank HM171537 and
Genbank HM572267 to HM572271]. Because of the lack of
available genetic information, eukaryotic DING proteins sequences
are very sparse and comprise, for the most of them, only some N-
terminal and internal peptides [5]. This lack of sequence
information has considerably hampered studies on DING proteins,
but opens a large field of investigation onto this family of proteins.
In humans, at least five different DING proteins have been
reported, generally identified in relation with a broad range of
diseases or biological processes [4]. The sequence divergence
observed between available pieces of sequences suggests that they
are not products of polymorphisms, editing or splicing mecha-
nisms. The Synovial Stimulatory Protein (SSP) was the first
discovered DING protein and was hypothesized to be related to
the etiology of rheumatoid arthritis [3]. The Crystal Adhesion
Inhibitor (CAI) was isolated by virtue of its capacity to inhibit the
formation of kidney stones [6]. Khan et al. reported the discovery
of the Steroidogenisis-Inducing Protein (SIP) and its potent activity
toward ovarian surface epithelium [7]. Recently, studies to define
the resistant factor from HIV resistant cells led to identification of
a new DING protein, X-DING CD4, that exhibits a human
immunodeficiency virus-1 (HIV-1) inhibition activity [8]. This
protein was only detectable in HIV-resistant cells, and its anti-
HIV-mediated activity was blocked by specific antibodies [8].
Finally, the Human Phosphate Binding Protein (HPBP) was
serendipitously discovered while performing structural studies on
human paraoxonase-1 (PON1), a high-density lipoprotein (HDL)
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associated apolipoprotein with anti-atherogenic activity [9]. PON1
is an extensively studied protein that exhibits paraoxonase,
lactonase and arylesterase activity, and participates in the
antioxidant defense system [10,11]. HPBP was found to form a
very tight complex with PON1 [12], and it has been shown to be
necessary for the stabilization of this protein [13,14,15]. The X-ray
structure of HPBP has been solved [9], and the combination of
crystallographic and mass spectrometry data has lead to the
obtaining of the first complete sequence of a DING protein [9,16].
Structural analysis of HPBP showed that DING proteins belong to
a superfamily of high affinity phosphate binding proteins. Thus,
HPBP may be considered as the first phosphate transporter
identified so far in humans. However, the function related to this
ability is still unknown. Recently, it has been shown that HPBP, as
for X-DING CD4, has an anti-HIV activity. Interestingly, HPBP
was also able to inhibit specific strains of HIV which are resistant
to treatment with zidovudine (AZT), an antiretroviral drug [17].
The HIV inhibition activity within the DING family has also
been described outside humans, for p27SJ and its full-length form
p38SJ, a plant DING protein from Hypericum perforatum [18]. The
biological role of this protein is not fully understood, but it is
however clear that its phosphatase activity influences the cell cycle
[19,20]. Additionally, it has been shown that p27SJ/p38SJ interact
with the viral protein Tat, the transcription factor C/EBP and the
RNA Polymerase II to inhibit HIV proliferation [18,20]. In fact,
p27SJ as well as X-DING CD4 and HPBP inhibit HIV replication
by targeting the transcription step in HIV cycle, a viral step that is
not yet targeted by the currently used therapies.
HIV-infection is still a public health problem, affecting more
than 33 million peoples in the world [21]. Current HIV therapies
are based on the using of at least three drugs belonging to two
different classes of antiretroviral drugs. Antiretroviral drugs can be
divided in seven classes: a) nucleoside reverse transcriptase
inhibitors (NRTIs); b) nucleotide reverse transcriptase inhibitors
(NtRTIs); c) nonnucleoside reverse transcriptase inhibitors
(NNRTIs); d) protease inhibitors (PIs); e) fusion inhibitors; f) co-
receptor inhibitors, and g) integrase inhibitors [21,22]. Drugs from
each class target a different stage of HIV replication cycle, but
none of them targets the transcription step. The discovery that
some DING proteins target this step of HIV cycle opens new
insights to understand the development of the disease, and might
be useful to develop new anti-HIV treatment strategies. The
presence in humans of two proteins with anti-HIV activity (HPBP
and X-DING CD4) is intriguing and request more investigations.
Thus, we carried out this study with the aim of exploring the
relationship between HIV infection and the DING proteins
concentration.
Materials and Methods
Study population
The study was performed on 207 HIV-infected patients (139
men, 68 women; mean age 38 years; range 22 to 66) attending the
outpatients clinics of the Hospital Universitari de Sant Joan. Of
these patients, 122 were co-infected by the hepatitis C virus
(HCV). HIV-infected patients were undergoing two different
treatment regimens. Fifty-two subjects were currently not receiving
any type of antiretroviral therapy for at least 6 months (13 patients
have never been treated and the 39 others stopped treatment more
than 6 months), and 155 had received continuous treatment with
an antiretroviral regimen containing zidovudine, stavudine or
lamivudine (NRTIs). In addition to this antiretroviral treatment,
HIV-infected patients were taking lopinavir/ritonavir (PIs; n = 71)
or efavirenz (NNRTI; n= 84) for at least 6 months. The exclusion
criteria were age under 18 years, renal function impairment
defined as creatinine levels higher than 106 mmol/l, or presence of
an AIDS-related opportunistic disease at the time of the study.
The main clinical characteristics of these patients are summarized
in Table S1. The control group consisted of 130 healthy volunteers
who participated in an ongoing epidemiological study being
conducted in our geographical area, and the details of which have
been previously reported [23]. All the volunteers had been invited
to attend a clinical examination and to provide a fasting blood
sample. There was no clinical or analytical evidence of renal
insufficiency, liver damage, neoplasia, or neurological disorders.
A fasting venous sample blood was obtained from all the
participants and serum was stored at 280uC until measurements
were performed. All the participants provided fully-informed
written consent to participation in the study on the understanding
that anonymity of all data is guaranteed. The study was approved
by the Ethics Committee of the Hospital Universitari de Sant Joan
de Reus (Institutional Review Board).
Determination of serum concentration of DING proteins
Serum concentration of DING proteins was measured by in-
house ELISA using rabbit polyclonal antibodies generated against
HPBP. Details of the purification methods and antibody
production have been previously reported [12,24]. Because of
the high sequence conservation between DING proteins, anti-
HPBP antibodies are able to recognize several representatives of
the DING family. As a standard, we used PfluDING (a DING
protein from Pseudomonas fluorescens that shares 77% sequence
identity with HPBP), with an initial concentration of 204 ng/ml,
prepared in phosphate buffered saline (PBS). The secondary
antibody was an anti-rabbit-IgG peroxidase conjugate (Invitrogen,
Carlsbad, USA), diluted 1:3,000 in PBS/1% BSA. The enzyme
substrate was tetramethylbenzidine (Sigma, St. Louis, MO, USA)
plus hydrogen peroxide. Tetramethylbenzidine (2 mg) was diluted
in 200 ml of dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO,
USA) and added to 20 ml of 0.1 M citrate/acetate buffer, pH 6.0,
with 72 ml urea hydrogen peroxide.
The ELISA procedure was the following: human serum samples
were diluted 1:1,000 in PBS. One hundred ml of sample or
standard were added to the plate wells and incubated overnight at
room temperature. After one wash with PBS, we added 150 ml of
PBS/1% BSA to block the remaining absorption sites, and left for
1 hour at room temperature. After three washes, we added 100 ml
of primary antibody (1:3,000) and incubated for 1 hour at room
temperature. After washing, we added 200 ml of secondary
antibody, and incubated the plates again for 1 hour at room
temperature. After washing, we added 200 ml of enzyme/substrate
solution and incubated for 15 min. The reaction was stopped with
50 ml of 2 M H2SO4, and the absorbance was read at 450 nm in
an automated microplate reader (BioTek Instruments Inc.,
Winooski, VT, USA). All the incubations were under gentle
shaking. The assays were performed on 96-well low binding plates
(Scientific Laboratory Supplies Ltd., Yorkshire, UK).
Other biochemical and serological measurements
Serum PON1 concentration was determined by in-house
ELISA with rabbit polyclonal antibodies generated against a
synthetic peptide with the sequence CRNHQSSYQTRLNAL-
REVQ that is specific of mature PON1 [25]. Serum PON1
lactonase activity was analyzed by measuring the hydrolysis of 5-
thiobutyl butyrolactone (TBBL) as previously described [26,27].
Serum PON1 paraoxonase activity was determined by measuring
the rate of hydrolysis of paraoxon [28]. Plasma HIV-1 viral load
was measured with the COBASH TaqManH HIV-1 assay (Roche,
DING Proteins Level Increases in HIV-Infection
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Basel, Switzerland) and CD4+ T-cell and CD8+ T cell counts by
flow cytometry (Coulter Epics XL-MLC, Beckman Coulter,
Fullerton, CA, USA). Antibodies against HCV, serum b-2-
microglobulin, a marker of lymphocyte destruction and progres-
sion of HIV-infection [29], and serum cholesterol, triglycerides,
HDL-cholesterol, and apolipoprotein A-I were measured in an
automated analyzer (UniCelTM DxI 800, Beckman Coulter,
Fullerton, CA, USA). LDL-cholesterol concentration was estimat-
ed by the Friedewald formula [30].
FPLC lipoprotein fractionation
DING proteins distribution in lipoproteins was investigated by
FPLC (Bio-Rad BioLogic DuoFlow 10 system, Bio-Rad Labora-
tories, Inc. Hercules, CA). Sera from 2 control subjects and 2
HIV-infected patients were pooled separately, 200 ml from each
pool were injected into a Superose 6/300 GL column (GE
Healthcare Europe GmbH, Glattbrugg, Switzerland), and 500 ml
fractions were collected. DING proteins levels, cholesterol and
triglycerides were analyzed in every fraction as previously
described.
Statistical analysis
The normality of distributions was determined with the
Kolmogorov-Smirnov test. Differences between two groups were
assessed with the Student’s t-test (parametric) or the Mann-
Whitney U test (non-parametric). Differences between multiple
groups were analyzed by the Kruskal-Wallis test. Pearson or
Spearman correlation coefficients were used to evaluate the degree
of association between variables. The SPSS 18.0 package was
employed for all statistical calculations. Receiver Operating
Characteristics (ROC) analysis was employed to investigate the
ability of DING proteins measurement to distinguish between
HIV-infected patients and controls [31]. The curve was plotted
using Xlstat software (Addinsoft, http://www.xlstat.com/en/
home/).
Infection of peripheral blood mononuclear cells (PBMC)
with HIV-1
PBMC were maintained in modified RPMI media. PBMC were
infected with the JR-FL strain of HIV-1 as follows. In all, 50 ng of
p24-containing virus stock was added to every 16106 cells. Cells
were incubated with virus stock in a small volume of serum-free
medium for 2 h at 37uC. The cells were then washed twice PBS,
and fresh medium was added. In parallel, control uninfected cells
were prepared four days post-HIV-1-infection. Cells were
harvested and analyzed by western-blot assay and ELISA as
described below. Western blot analysis was performed with protein
extracts using anti-HPBP, and anti-tubulin antibodies according to
standard procedures.
p24 ELISA
Approximately 16106 PBMC were infected with HIV-1 JF-RL.
Six days post-infection, supernatants were collected and analyzed
for the presence of p24 by ELISA assay using p24 ELISA Assay kit
purchased from BioChain (BioChain Institute, Inc., Hayward,
CA). The assay was measured spectrophotometrically using
450 nm filter to indicate the concentration of p24 reactive
determinants present in samples.
Results
DING proteins concentration is increased in HIV-infected
patients
Serum DING proteins concentration was significantly increased
in HIV-infected patients with respect to the control group [18.3
(11.0–28.3) vs. 7.9 (4.2–11.2) mg/l, respectively; p,0.001]
(Fig. 1A). The diagnostic value of our ELISA dosage was
investigated using ROC curve by plotting the true positive rate
(sensitivity) against the false positive rate (1- specificity). The best
diagnostic test is a test in which the curve is the most closer to the
upper left corner of the graph. The accuracy of the test is
measured by the area under the curve (AUC) which could be
different from 0.5 (non discrimination) and the closest to 1. Our
ROC analysis showed an AUC of 0.813 (95%CI: 0.769 to 0.858).
This value, close to 1.0 indicates that measuring DING proteins
concentration may be considered as a potential predictive factor
for HIV-infection (Fig. 1B).
Relationships between serum DING proteins
concentration, PON1 status and lipoprotein alterations
Results are summarized in Fig. 2 and Table 1. HIV-infected
patients had an altered lipoprotein profile with an increase in
Figure 1. DING proteins concentrations and ROC curve obtained for the ELISA assay. (A) Variation of concentration between HIV-infected
patients and controls; results are represented as medians and interquartile range (IQR). (B) ROC curve obtained for the ELISA assay; dashed line show
the line of non discrimination.
doi:10.1371/journal.pone.0033062.g001
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serum triglycerides concentration and a decrease in cholesterol in
LDL and HDL fractions. A significant direct relationship was
observed between serum DING proteins and PON1 concentra-
tions in HIV-infected patients (r= 0.465; p,0.001; Fig. 2A), and
an inverse relationship between DING proteins and PON1
lactonase (r=20.255; p,0.001; Fig. 2B) and paraoxonase
activities (r=20.189; p = 0.008; Fig. 2C). DING proteins
concentration was also inversely associated with serum cholesterol
(r=20.406; p,0.001; Fig. 2D), LDL-cholesterol (r=20.310;
p,0.001), HDL-cholesterol (r=20.174; p = 0.016), serum triglyc-
erides (r=20.146; p = 0.050), and apolipoprotein A-I (r=20.221;
p = 0.002) concentrations.
Figure 2. Relationship between DING proteins concentration, PON1 status and cholesterol. Correlation of DING proteins concentration
with: (A) serum PON1 concentrations, (B) PON1 lactonase activity, (C) PON1 paraoxonase activity and (D) cholesterol concentration in HIV-infected
patients.
doi:10.1371/journal.pone.0033062.g002
Table 1. Selected biochemical parameters in the control group and in HIV-infected patients.
Parameter
Control group
(n=130)
HIV-infected
patients (n =207) p*
Untreated
(n=52)
Treated
(n=155) p{
Cholesterol (mmol/L) 5.28 (0.98) 4.89 (1.23) ,0.001 4.47 (0.93) 5.03 (1.29) 0.007
Triglycerides (mmol/L) 1.1 (0.5–2.6) 1.5 (0.6–8.5) ,0.001 1.1 (0.6–4.1) 1.8 (0.7–8.6) ,0.001
HDL-cholesterol (mmol/L) 1.48 (0.39) 1.18 (0.45) ,0.001 1.19 (0.37) 1.17 (0.46) NS
LDL-cholesterol (mmol/L) 3.20 (0.95) 2.75 (0.96) ,0.001 2.57 (0.79) 2.82 (1.01) NS
Apolipoprotein A-I (g/L) 1.69 (0.28) 1.38 (0.31) ,0.001 1.38 (0.31) 1.38 (0.31) NS
PON1 concentration (mg/L) 96.5 (43.6–291) 98.9 (14.1–347) NS 115.9 (13.7–571) 93.5 (13.7–338) 0.06
PON1 lactonase activity (U/L) 5.4 (3.2–8.8) 5.2 (2.8–8.5) NS 4.9 (2.3–8.1) 5.1 (2.9–8.3) NS
PON1 paraoxonase activity (U/L) 278.2 (161–580) 285.7 (153–679) NS 275.3 (123–678) 285.9 (171–709) NS
Results are presented as means and SD in parentheses (parametric) or as medians and 95% CI in parenthesis (nonparametric). NS: Not significant.
*Control group versus all HIV-infected patients.
{Treated versus untreated HIV-infected patients.
doi:10.1371/journal.pone.0033062.t001
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FPLC lipoproteins fractionation
In the control pool, DING proteins were eluted in HDL
fractions, together with PON1, but also in IDL particles, an
intermediate form between VLDL and LDL. A substantial
amount of DING proteins was observed in the lipoprotein
deficient serum (LPDS) from fractions 25 to 45, corresponding
to soluble, free or DING proteins bound to albumin or other
serum proteins. The HIV-infected pool showed a similar pattern
of distribution, but with a global increase that was especially
marked in the HDL and free DING proteins fractions (Fig. 3).
Relationships between serum DING proteins
concentration and the immunological and virological
outcomes
DING proteins concentration was directly associated with viral
load (r=0.332; p,0.001). HIV-infected patients with a negative
HIV-1 plasma viral load had significantly lower serum DING
proteins concentration than those with a positive viral load [14.6
(2.7–48.0) vs. 24.1 (7.5–50.5) mg/l, respectively; p,0.001]. A
highly significant inverse association was observed between serum
DING proteins concentration and CD4+ T cell counts
(r=20.275; p,0.001) (Fig. 4A), and with the CD4+/CD8+ ratio
(r=20.270; p = 0.001). There was a highly significant linear direct
relationship between serum DING proteins and b-2-microglobulin
concentrations (r=0.666; p,0.001; Fig. 4B). Co-infection with
HCV was also associated with a significantly higher serum DING
proteins concentration [21.0 (4.8–56.8) vs. 14.6 (3.5–44.5) mg/l,
respectively; p= 0.016].
Influence of treatments on serum DING proteins
concentrations in HIV-infected patients
Serum DING proteins concentration was significantly affected
by the type of antiretroviral treatment followed. As shown in
Fig. 5A, both untreated HIV-infected patients and patients treated
with PIs had higher levels of DING proteins than those
undergoing a NNRTIs-based antiretroviral treatment regimen
[26.9 (17.4–38.9) and 24.0 (15.4–34.5) vs 17.2 (8.4–26.3) mg/l;
respectively]. Moreover, we observed a significant inverse
Figure 3. DING proteins distribution in lipoproteins fractions from HIV-infected and control pool. Pools of two HIV-infected patients and
two controls were used in this experiment; results are represented as the optical densities at 450 nm.
doi:10.1371/journal.pone.0033062.g003
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relationship between serum DING proteins concentration and the
duration of the antiretroviral treatment with NNRTI (r=20.309;
p = 0.012), but not in HIV-infected patients receiving PIs
(r=20.059; p = 0.408) (Fig. 5B).
In vitro HIV-infection of cell culture
Infection of human PBMC with HIV-1 caused overproduction
of DING proteins detected by monoclonal anti-HPBP antibody
(Figure 6 A, top panel, lane 2) compared to uninfected cells (Lane
1). HIV-1 replication on the sixth day post-infection was also
confirmed by p24 ELISA for the presence of HIV-1 p24 protein
(Figure 6 B). Data from this experiment suggest that DING
proteins seem to be expressed in response to HIV infection.
Discussion
Recent studies on DING proteins have highlighted the anti-
HIV potential of some members of this family [8,17,18,20].
During this study, we have developed a homemade ELISA for the
quantification of serum DING proteins. Using this method, we
were able to measure for the first time the concentration of serum
DING proteins in healthy people (7.9 (4.27–11.24) mg/l). In
contrast, our results show that DING proteins concentration was
increased in both serum and lipoproteins fractions of HIV-infected
patients with respect to controls. This increase is likely to be a
response of the organism to HIV infection. However, the
pathophysiological significance of this increase remains unclear.
In addition, cell cultures infected with HIV show also an
overexpression of DING proteins. This overexpression was not
related to treatment side effects since these cells were not treated
with any antiretroviral medication.
Expression of DING proteins in response to HIV-infection has
been previously reported by Simm et al. [32,33]. Indeed, it has
been shown that primary CD4+ T cells exposed to an attenuated
form of HIV-1 (Dvif HIV-1) acquire resistance to the wild-type
virus [32,33]. Interestingly, these resistant cells were permissive to
virus entry, reverse transcription of RNA, integration of the viral
genome in the DNA of the cell, but were able to block
transcription of HIV-1 genes [33]. Moreover, it has been shown
that this phenotype was mediated via the production of a DING
protein that they have named X-DING CD4 (formerly HIV
resistance factor or HRF) [8]. Recently, it has been shown that
HIV-exposure of these resistant cells causes a rapid up-regulation
of X-DING CD4 at the mRNA level [34]. Given this potent anti-
HIV activity, the author proposed that this factor may be
considered as a part of an ancient defense mechanism of the
organism against HIV [34,35]. In fact, recent discoveries have
shown that human cells are able to produce a so called ‘‘restriction
factors’’ that interfere with HIV and other retroviruses replication.
Particularly, APOBEC3, Tethrin, TRIM5, defensins and other
antiretroviral factors has been shown to block HIV at different
stages of its replication cycle [35,36,37,38]. It has been proposed
that these factors could be part of an ancient defense mechanism
against HIV, which has otherwise evolved a ‘‘toolkit’’ to overcome
their effects. From the known anti-HIV potential of some human
DING representatives, it is not to be excluded that DING proteins
may make part of this unusual defense mechanism against HIV or
other viruses.
We have also observed a significant direct relationship between
DING proteins and PON1 concentration in HIV-infected
patients. This increase may be explained by the recently described
association between PON1 and the DING protein HPBP. Indeed,
in human plasma HPBP and PON1 were found to be tightly
associated, and it has been shown that this association is required
for the stability of each other [13,14]. However, an inverse
relationship was observed between the concentration of DING
proteins and both PON1 lactonase and paraoxonase activities. In
fact, it is known that PON1 activities are greatly modulated by its
molecular environment on HDL particles. In addition, PON1
need to be bound to HDL for its optimum activity [39]. Since
PON1 can be tightly associated with HPBP on HDL surface, a
modulation of its activity by HPBP seems to be possible.
Our experiments on the fractionation of lipoproteins give new
information about DING proteins localization. Our results show
that DING proteins are localized mainly on HDL and IDL
Figure 4. Relationship between DING proteins concentrations
and some HIV markers. Correlation of DING proteins concentration
with (A) CD4+ T cell counts and (B) b-2-microglobulin in HIV-infected
patients.
doi:10.1371/journal.pone.0033062.g004
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particles, an intermediate form between VLDL and LDL. Given
the association between HPBP and the HDL-associated PON1, it
seems that DING proteins found on IDL are directly linked or in
association with other proteins. We found also a substantial
amount of DING proteins in a free form in the LPDS fractions.
This finding indicates that DING proteins may also be present in
free form as circulating proteins, maybe in association with other
proteins, but not linked to any lipoprotein particle. Identification
of these putative partners will be helpful to better understand their
physiological functions.
We investigated the relationship between DING proteins
concentration and several HIV markers like CD4 counts, b-2-
microglobulin and viral load. Our results show an inverse
relationship between DING proteins concentration and CD4
counts. Interestingly, a very strong direct association with b-2-
microglobulin has been observed. It is worth to be noted that
Figure 5. Influence of treatment on DING proteins concentration. (A) Effect of PIs and NNRTIs based treatment on DING proteins
concentration compared to naives HIV-infected patients; results are represented as medians and IQRs. (B) Relationship between DING proteins
concentration and type/duration of NNRTIs or PIs treatment.
doi:10.1371/journal.pone.0033062.g005
Figure 6. In vitro HIV-infection of cell culture and its impact on the expression of DING proteins. (A) Expression of DING proteins
detected by western blot using anti-HPBP antibody in HIV-infected cells (right panel) or non infected control cells (left panel). (B) p24 antigen
quantified 6 days post-infection using a p24-ELISA.
doi:10.1371/journal.pone.0033062.g006
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many studies consider b-2-microglobulin as an effective marker of
HIV disease progression [29,40]. Combined with our results from
ROC curve analysis, we suggest that serum DING proteins dosage
may be considered as a potential predictor factor of HIV. In
addition, DING proteins concentration was directly associated
with the viral load. Interestingly, HIV-infected patients with a
negative viral load kept a relatively high concentration of DING
proteins compared to controls. It seems that once infected, the
organism stay producing relatively high amounts of DING
proteins. The molecular mechanisms responsible of this response
are still unknown and need to be further studied.
Another intriguing finding was the effect of treatment on the
DING proteins concentration. In fact, in contrary to antiproteases,
treatment with non-nucleoside reverse transcriptase inhibitors was
correlated with a decrease of DING proteins concentration. It
seems possible that overexpression of DING proteins occurs
between these two steps targeted by the therapy. May viral
genome integration induce DING proteins overexpression?
Indeed, many studies have shown that HIV infection can
modulate the expression of several genes [41,42]. Hence, a direct
implication of HIV on the expression of DING proteins is not to
be excluded.
Our results, together with the presence in humans of DING
proteins with anti-HIV activity (HPBP and X-DING CD4), raise a
major question of why this increase is not correlated with a
resistance to HIV infection. One possibility is that DING proteins
are not ‘‘bioavailable’’ and cannot inhibit HIV when associated
with other proteins. For instance, HPBP is not active against HIV
when associated with PON1 [17]. So we can think about a
mechanism in which DING proteins need to be released from
their partners to be able to exercise their functions.
In summary, results from this study show that human organism
reacts to HIV infection by an overexpression of DING proteins.
This overexpression was also observed in the in vitro infection of
cell cultures, ruling out any influence of treatment on this increase.
This may have a prognostic value to assess HIV infection in newly
or already treated HIV-infected patients. Anyway, DING proteins
stay enigmatic, and further studies are needed to deepen our
knowledge on this family of proteins.
Supporting Information
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